Related Experiment Video
Updated: Dec 26, 2025
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
The Anti-Breast Cancer Potential of Bis-Isatin Scaffolds
1School of Chemistry and Life Science, Anshan Normal University, Liaoning, China.
Aim:
To develop novel anti-breast cancer agents and discuss the structure-activity relationship of bis-isatin scaffolds.
Background:
Breast cancer is the most common invasive cancer and the second leading cause of cancer death in women after lung cancer. Bis-isatin scaffolds possess potential anti-breast cancer activity, and some of them such as Indirubin could induce cancer cells apoptosis via multiply mechanisms.
Objective:
The primary objective of this study was to evaluate the potential of bis-isatin scaffolds with alkyl/ether linkers between the two isatin moieties against different human breast cancer cell lines including MCF-7, AU565, MDA-MB-231, MDA-MB-435 and MDA-MB-468 cells.
Methods:
The synthesized bis-isatin scaffolds with alkyl/ether linker between the two isatin moieties were evaluated for their in vitro activity against MCF-7, AU565, MDA-MB-231, MDA-MB-435, and MDA-MB-468 human breast cancer cell lines by MTT assay.
Results:
All the synthesized compounds (IC50: 38.3-197.6 µM) possess considerable activity against MCF-7, AU565, MDA-MB-231, MDA-MB-435, and MDA-MB-468 human breast cancer cell lines, and the most potent compound 4e (IC50: 38.3-63.5 µM) was no inferior to Cisplatin (IC50: 20.1-38.6 μM) against the five tested human breast cancer cell lines.
Conclusion:
All the synthesized bis-isatin scaffolds were active against a panel of breast cancer cell lines, highlighting the significance of exploring the bis-isatin scaffolds to fight against breast cancers. The enriched structure-activity relationship may set up the direction for the rational design and development of novel bis-isatin scaffolds with higher efficiency.
Insights
Novel bis-isatin scaffolds show significant anti-breast cancer potential. These compounds demonstrate considerable activity against multiple human breast cancer cell lines, offering a promising avenue for developing new cancer therapies.
Area of Science:
- Medicinal Chemistry
- Oncology
- Drug Discovery
Background:
- Breast cancer is a leading cause of cancer death in women.
- Bis-isatin scaffolds exhibit potential anti-breast cancer properties.
- Indirubin, a related compound, induces cancer cell apoptosis through various mechanisms.
Purpose of the Study:
- To synthesize and evaluate novel bis-isatin scaffolds with alkyl/ether linkers.
- To assess the anti-breast cancer activity of these compounds against diverse human breast cancer cell lines.
- To explore the structure-activity relationship (SAR) of these novel agents.
Main Methods:
- Synthesis of bis-isatin scaffolds with varying alkyl/ether linkers.
- In vitro evaluation of synthesized compounds using the MTT assay.
- Testing against a panel of human breast cancer cell lines (MCF-7, AU565, MDA-MB-231, MDA-MB-435, MDA-MB-468).
Main Results:
- All synthesized bis-isatin scaffolds displayed considerable in vitro activity.
- Compound 4e showed potent activity (IC50: 38.3-63.5 µM) against all tested cell lines.
- The efficacy of compound 4e was comparable to Cisplatin (IC50: 20.1-38.6 µM).
Conclusions:
- Synthesized bis-isatin scaffolds are effective against a range of breast cancer cell lines.
- These findings underscore the therapeutic potential of bis-isatin scaffolds in breast cancer treatment.
- Established SAR provides a foundation for designing more potent and efficient bis-isatin derivatives.
More Related Videos
08:32Analysis of Cancer Cell Invasion and Anti-metastatic Drug Screening Using Hydrogel Micro-chamber Array HMCA-based Plates
Published on: October 25, 2018
11:06Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells
Published on: May 20, 2015
